secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0000950170-24-086039
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking advances VK2735 to Phase 3 for obesity; Q2 net loss $22.3M
-----------------------------------------------------------------

- VK2735 to advance to Phase 3 after positive VENTURE study; End-of-Phase 2 meeting with FDA planned for 2H24.
- Oral VK2735 Phase 2 trial in obesity expected to start in 4Q24; 28-day weight loss up to 5.3% from baseline.
- VK2809 met secondary endpoints in NASH/fibrosis; NASH resolution rates 63-75% vs 29% placebo; End-of-Phase 2 meeting 4Q24.
- Q2 net loss $22.3M ($0.20/share) vs $19.2M ($0.19) year ago; R&D expenses rose to $23.8M.
- Cash and investments $942M at June 30, 2024, up from $362M at year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024086039/0000950170-24-086039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017024086039/vktx-20240724.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-086039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer